- Piramal Pharma reported a consolidated net loss of Rs 69.4 crore for Q1 FY27
- Revenue rose 17.4% year-on-year to Rs 2,270 crore in the quarter ended June 30
- EBITDA increased 82.9% to Rs 195 crore compared to Rs 107 crore last year
Piramal Pharma Ltd. reported a narrower consolidated net loss for the first quarter of FY27, supported by double-digit revenue growth and a sharp improvement in operating margins.
The company posted a consolidated net loss of Rs 69.4 crore for the quarter ended June 30, compared with a loss of Rs 81.7 crore in the corresponding period last year, according to the company's quarterly earnings filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Revenue from operations rose 17.4% year-on-year to Rs 2,270 crore, up from Rs 1,934 crore a year earlier.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
ALSO READ: Star Health Q1 Results: Profit Surges 26% To Rs 550 Crore; Insurance Revenue Rises
Operating performance improved significantly during the quarter. Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 82.9% to Rs 195 crore, compared with Rs 107 crore in the year-ago period.
The company's EBITDA margin expanded to 8.6%, from 5.5% in the corresponding quarter last year, reflecting stronger operating leverage and improved profitability.
Piramal Pharma Q1 (Consolidated, YoY)
• Net Loss at Rs 69.4 crore versus loss of Rs 81.7 crore
• Revenue up 17.4% to Rs 2,270 crore versus Rs 1,934 crore
• Ebitda up 82.9% to Rs 195 crore versus Rs 107 crore
• Ebitda Margin at 8.6% versus 5.5%
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
